Category:

Release – Ocugen, Inc. to Present at Upcoming Vaccines, Cell and Gene Therapy Conferences

Posted on by aweinsoff@channelchek.com

Research, News, and Market Data on OCGN

October 6, 2022

MALVERN, Pa., Oct. 06, 2022 (GLOBE NEWSWIRE) — Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Company will present at two important conferences this month.

“I look forward to sharing more about our Modifier Gene Therapy platform—a novel approach to treating inherited retinal disease—during the Meeting on the Mesa, and Dr. Hopkins will provide more on COVAXIN™— a whole-virion inactivated COVID-19 vaccine candidate currently in a Phase 2/3 immuno-bridging and broadening clinical trial with the U.S. FDA—at the Vaccines Summit,” said Dr. Shankar Musunuri, PhD, MBA, Chairman, CEO & Co-Founder of Ocugen. “It’s critical that we participate in conversations about the next generation of medicine among our peers and share our contributions to the advancement of vaccines, cell and gene therapy.”

2022 Cell & Gene Meeting on the Mesa

Title: Our Commitment to Gene & Cell Therapy
Presenter: Dr. Shankar Musunuri
Date: Wednesday, October 12, 2022
Time: 2 p.m. PT
Location: Park Hyatt Aviara, Carlsbad, CA

Vaccines Summit 2022

Title: COVAXIN™: A whole SARS-CoV-2 virion inactivated vaccine against COVID-19
Presenter: Robert J. Hopkins, MD, MPH & TM, FACP, FIDSA, Chief Medical Officer
Date: Wednesday, October 12, 2022
Time: 6:10 – 6:30 p.m. ET
Location: Sheraton Reston Hotel, Reston, VA

About Ocugen, Inc.
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. We are making an impact on patient’s lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, and we are advancing research in infectious diseases to support public health and orthopedic diseases to address unmet medical needs. Discover more at www.ocugen.com and follow us on Twitter and LinkedIn.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.

Contact:
Tiffany Hamilton
Head of Communications
IR@ocugen.com

Reading Between Michael Burry’s Lines

Posted on by phoffman@channelchek.com
Image Source: @michaeljburry (Twitter)

Michael Burry’s Advice for Companies to Become Better Values

After my morning coffee and check on stock futures, I peruse Twitter. Coffee is necessary when you may need to translate cryptic messages from tweeters like Dr. Michael Burry. This week, the hedge fund manager, famous for his foresight and creativity in shorting subprime mortgages before the mortgage crisis in 2008, has been very active on the microblogging platform. Two tweets from October 5th are newsworthy, considering their source, their insight, and the concern they convey are described below.

The first reads: “Low price/cash flow businesses are different today vs. 2000 because they will buy back stock, buy back debt at a discount, and in general manage capital structure better. Makes them statistical value – math problems that more or less must work out.”

The second says, “Companies that are heavily leveraged but have the cash flow and termed out debt have options today, including reducing their debt loads at a significant discount brought on by higher rates. But as Graham said, in such a case, better off buying the stock.”

Taking these two tweets together, they make sense. Twenty years ago, interest rates were the lowest they had been since 1965; during the last week in December, plummeting 30-year mortgage rates had broken below 6%. Despite cheaper money, corporate treasurers and finance officers didn’t use the situation to shore up their capital structure and build a better base to grow on. The equity markets were weak from August 2000 until May 2009, after the financial crisis that in part came about because of how the cheap money was used.

Companies that are not stretched and are earning money today have the choice of strengthening their financial foundation by either buying their stock at today’s bearish prices. A stock buyback has the effect of reducing shares available in the market as they are now in the company’s treasury. Reduced float tends to increase the price and benefits shareholders. The company does have the option of selling these shares should an opportunity present itself where it would like to raise capital selling previously available shares.

Burry also mentions leveraged companies. Having just come off of 40-year lows in interest rates, it was, in many cases, prudent for companies to leverage themselves with cheap money. These loans, present-valued at today’s higher rates, can be negotiated and paid off at a discount. For companies with adequate cash flow, they may be able to substantially reduce debt for a fraction of the principal amount. Here is how to best get your head around this, if you are a lender and the borrower is paying you 2%, and rates are now 6%, how much less than the borrowed amount would the borrower have to give you in order for you to do better than breaking even? You can lend one-third of the money at 6% and earn the same cash amount. So the borrower is in a great negotiating position.

Michael Burry makes no secret of the fact that he is an avid reader. “Graham” refers to Benjamin Graham the “father of value investing.” Burry reminds us that, according to this historically significant, well-published value investor, investors and companies are generally better off buying back their own stock.

Take Away

There are showmen that are on TV and keep their jobs by keeping viewers glued to their TV sets, and there are others that comment on the market for less-commercial reasons. Those on TV and writing on well-read sites like Yahoo Finance are worth reading to understand what others are reading. Proven, outside the mainstream thinking is worth paying attention to in order to diversify the information your weighing as an investor.

You can even think of it this way; no one pays Burry for advertising on Twitter accounts used by Burry or some other well-followed investors. Whereas mainstream news only exists because of paid-for advertising from companies and industries that they cover. This doesn’t mean he will always be correct, but, who might be less biased?

Paul Hoffman

Managing Editor, Channelchek

Source

Twitter @michaeljburry

The Biotech Field That’s Getting Big Pharma’s Attention at the Earliest Stages

Posted on by aweinsoff@channelchek.com
Image Credit: Ed Schipul (Flickr)

Small Biotech Field with Big Promise

A silver bullet cure, with possible indications for 150 illnesses or more, is now being researched by a few small biotech companies. The results have gotten the attention of big pharmaceutical companies.

In the world of biology, medicine, and biotechnology, there’s a new and extremely promising field of research in inflammasomes. Since the discovery 20 years ago, increasing understanding of what causes inflammation or an inflammatory response in humans and the knowledge of the mechanisms and role of inflammasomes has developed into a race to design potential drugs which target the culprit in many diseases. The problem to be solved is an overly zealous inflammatory response.

The activation of the inflammation system is to protect the body from pathogens, injury, or other dangers or irritants. While insufficient inflammation can lead to persistent infection or problems related to the initial trigger, excessive inflammation can cause chronic or systemic inflammatory diseases. While there are many medications, both over-the-counter and by prescription, to help reduce inflammation and problems associated with it, a therapy or therapies upstream could prevent an over-inflammation response at the source.

Currently, the rapid expansion of knowledge of inflammasomes’ role in various diseases has uncovered links to neurological diseases such as Parkinson’s, Alzheimer’s, and MS; metabolic disorders including type2 diabetes, and obesity; and cardiovascular diseases.

Currently, there are no approved inflammasome inhibitors; however, there are several promising early-stage trials occurring at a few focused companies. Development of therapies is the goal, with expectations of them being able to treat a myriad of ailments. Success could be similar to the discovery of penicillin when many infections quickly ceased being worrisome. The breakthrough could provide therapy or a mechanism to control one or two key inflammasomes that could suddenly provide cures or relief from many chronic problems.

Over the past few years, these inflammasome-related transactions, acquisitions, and partnerships have taken place:

Ventus Therapeutics- On September 29, 2022, Ventus received $70 million upfront, with the agreement for additional milestones of up to $633 million, also royalty payments and R&D funding from Novo Nordisk to license Ventus’s brain penetrant inflammasome (NLRP3) inhibitor – Ventus is a privately held company that retains full rights.

Cerevance – August 9, 2022 Cerevance received $25 million upfront, with the agreement for additional milestones up to $1.1 billion, with potential for royalty payments from Merck on sales of approved products derived from the strategic research collaboration of Alzheimer’s targets using Cerevance’s NetSseq platform. (Pre-clinical phase)

Inflamazome – September 21, 2020 Inflamazome was fully acquired for $451 million upfront with R&D milestones that could be worth up to $1.125 billion from Roche. Roche will own full rights to the acquired company’s portfolio of oral NLRP3 small molecule inflammasome inhibitors. (Pre-clinical phase and Phase 1)

IFM Therapeutics – Quattro & IFM Discovery (Incubator) – December 2019, Has raised $55.5 million to launch its third drug subsidiary as well as an incubator, both of which are focused on developing new therapies for inflammatory diseases and cancers. Omega Funds was the lead, with Atlas Ventures also participating. Financing lead: Omega Funds also participating: Atlas Ventures. (Discovery Phase)

Inflammasome Therapeutics – September 2019,  Is entitled to receive up to $160 million in milestone and gated development payments and tiered royalties and other milestones due on commercialization from Boehringer Ingelheim. (Development Phase)

IFM Therapeutics – September 2019, Agreement provides sufficient funding for research and development costs through late-stage pre-clinical development of the lead program with an option to acquire IFM Due. IFM is a Privately held company. (Discovery Phase)

IFM Therapeutics- April 1, 2019, the subsidiary IFM Tre was acquired by Novartis. Novartis will pay $310 million upfront and up to roughly $1.3 billion in milestones to access three early-stage NLRP3 antagonists: IFM-2427, a systemically acting compound that began its first human studies last week, and two pre-clinical compounds: one gut-penetrating, and the other directed at the central nervous system. (Clinical Phase and Pre-clinical Phases)

Most of the small companies involved in inflammasome research are privately held and raise capital privately. From time to time, Noble Capital Markets may be involved in raising capital for non-public biotech firms and companies in other industries. To determine in advance if you qualify to invest in non-public capital raises, visit here to request accreditation.

Take Away

There are huge amounts of capital coming primarily from big pharma and venture capital firms with the expectation that R&D on inflammasomes could yield big results. Therapies that could regulate a primary culprit across many diseases would be a significant boost to investors and mankind.

Paul Hoffman

Managing Editor, Channelchek

https://www.channelchek.com/news-channel/inflammasomes_panel_from_noblecon16

https://www.sciencedirect.com/science/article/abs/pii/S0091674916302834

https://www.frontiersin.org/articles/10.3389/fimmu.2022.834289/full

https://www.ventustx.com/news/ventus-therapeutics-enters-exclusive-development-and-license-agreement-

https://cerevance.com/2022/08/09/cerevance-establishes-strategic-research-collaboration-with-merck-for-the-discovery-of-novel-targets-in-alzheimers-disease/

https://www.biospace.com/article/roche-dives-into-nlrp3-inflammasome-inhibition-with-acquisition-of-inflazome/

https://www.biospace.com/article/roche-dives-into-nlrp3-inflammasome-inhibition-with-acquisition-of-inflazome/

https://xconomy.com/boston/2019/12/02/ifm-lands-55-5m-to-launch-newco-quattro-and-discovery-incubator/

https://www.inflam.com/images/pdfs-doc/Inflammasome_BI_release_September_20_2019_1.pdf

https://www.ifmthera.com/news/ifm-therapeutics-announces-collaboration-and-exclusive-option-agreement-for-cgas-sting-focused-subsidiary-ifm-due/

https://cen.acs.org/pharmaceuticals/Novartis-acquire-inflammasome-focused-IFM/97/web/2019/04

https://www.the-scientist.com/bio-business/pharma-looks-to-inflammasome-inhibitors-as-all-around-therapies-68582

Release – Motorsport Games Announces Le Mans Virtual Series Ready for a Competitive 4 Hours of Monza

Posted on by aweinsoff@channelchek.com

Research, News, and Market Data on MSGM

  • Entry list for Monza revealed
  • Timetable for the weekend of racing

MIAMI, Oct. 05, 2022 (GLOBE NEWSWIRE) — Motorsport Games Inc. (NASDAQ: MSGM) (“Motorsport Games”), a leading racing game developer, publisher and esports ecosystem provider of official motorsport racing series throughout the world, announces today the entry list for the second round of the 2022-23 Le Mans Virtual Series, 4 Hours of Monza. The list is available (HERE). The high level of both real life and sim drivers due to compete in the upcoming Monza event is a great indication that another closely contested race is likely from start to finish.

Names such as 2021 ELMS champion Yifei Yi, Mexican motorsport legend Luis Diaz and Porsche factory driver Ayhancan Güven will be racing alongside esports elite, including those representing Bahrain victors Floyd Vanwall-Burst (Dillmann/Simončič/Pedersen) in LMP and Oracle Red Bull Racing (Webster/Siebel/Jordan) in GTE.

The race will take place on the rFactor2 platform at the virtual Autodromo Nazionale Monza and full, uninterrupted coverage will begin from 12:40 p.m. BST (CEST = +1 hour / EST = -5 hours) on Saturday, October 8. The Italian temple of speed is unmatched for its history and the passion it invokes in motorsport fans – real or virtual – and esport racing fans can be sure that plenty of action will be in store!

A total of 40 cars will battle it out in two different classes – 24 in LMP, with all competitors using an ORECA 07 LMP2 model, and 16 in GTE with teams having a choice of Ferrari, BMW, Porsche and Aston Martin Vantage models. Manufacturer support also comes to teams representing Alpine and Mercedes AMG.

Qualifying begins on Friday, October 7 at 6:00pm BST, and all race action can be followed on the FIA WEC, Le Mans and TraxionGG’s YouTube channels, on twitch.tv/traxiongg, and on multiple social media channels.

For further media information, contact Fiona Miller, Miller Media & Communications, on +44 7770 371332 or media@lemansvirtual.com

www.lemansvirtual.com

About Le Mans Virtual Series
Le Mans Virtual Series is a global, elite esports series made up of five rounds which bring together endurance racing and sim racing’s top teams to compete on some of the world’s most famous racetracks. International FIA-licensed real-world drivers are teamed up with elite esports squads to take on endurance classics for a total prize fund of US$250,000, culminating in the prestigious 24 Hours of Le Mans Virtual. Le Mans Virtual Series is a joint venture between leading racing game developer, publisher and esports ecosystem provider of official motorsport racing series throughout the world, Motorsport Games, and the Automobile Club de l’Ouest (ACO) – the creator and organizer of the world-famous 24 Hours of Le Mans and promoter of the FIA World Endurance Championship (FIA WEC).

Round 18 Hours of Bahrain, BahrainSeptember 17, 2022
Round 24 Hours of Monza, ItalyOctober 8, 2022
Round 36 Hours of Spa, BelgiumNovember 5, 2022
Round 4500 Miles of Sebring, USADecember 3, 2022
Round 524 Hours of Le Mans VirtualJanuary 14/15, 2023

About Motorsport Games:
Motorsport Games, a Motorsport Network company, is a leading racing game developer, publisher and esports ecosystem provider of official motorsport racing series throughout the world. Combining innovative and engaging video games with exciting esports competitions and content for racing fans and gamers, Motorsport Games strives to make the joy of racing accessible to everyone. The Company is the officially licensed video game developer and publisher for iconic motorsport racing series across PC, PlayStation, Xbox, Nintendo Switch and mobile, including NASCAR, INDYCAR, 24 Hours of Le Mans and the British Touring Car Championship (“BTCC”), as well as the industry leading rFactor 2 and KartKraft simulations. RFactor 2 also serves as the official sim racing platform of Formula E, while also powering Formula 1™ centers through a partnership with Kindred Concepts. Motorsport Games is an award-winning esports partner of choice for 24 Hours of Le Mans, Formula E, BTCC, the FIA World Rallycross Championship and the eNASCAR Heat Pro League, among others. Motorsport Games is building a virtual racing ecosystem where each product drives excitement, every esports event is an adventure and every story inspires.

Forward-Looking Statements:
Certain statements in this press release which are not historical facts are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are provided pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not statements of historical fact may be deemed forward-looking statements. Words such as “continue,” “will,” “may,” “could,” “should,” “expect,” “expected,” “plans,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, but are not limited to, statements concerning the timing, participants and expected benefits of the 2022-23 Le Mans Virtual Series, 4 Hours of Monza event. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, many of which are generally outside the control of Motorsport Games and are difficult to predict. Examples of such risks and uncertainties include, without limitation: difficulties, delays in or unanticipated events that may impact the timing and expected benefits of the 2022-23 Le Mans Virtual Series, 4 Hours of Monza event, such as due to unexpected changes in the event participants, as well as less than anticipated participation in or viewership of the event. Factors other than those referred to above could also cause Motorsport Games’ results to differ materially from expected results. Additional factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements can be found in Motorsport Games’ filings with the Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10-K for the fiscal year ended December 31, 2021, its Quarterly Reports on Form 10-Q filed with the SEC during 2022, as well as in its subsequent filings with the SEC. Motorsport Games anticipates that subsequent events and developments may cause its plans, intentions and expectations to change. Motorsport Games assumes no obligation, and it specifically disclaims any intention or obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law. Forward-looking statements speak only as of the date they are made and should not be relied upon as representing Motorsport Games’ plans and expectations as of any subsequent date. Additionally, the business and financial materials and any other statement or disclosure on, or made available through, Motorsport Games’ website or other websites referenced or linked to this press release shall not be incorporated by reference into this press release.

Website and Social Media Disclosure:
Investors and others should note that we announce material financial information to our investors using our investor relations website (ir.motorsportgames.com), SEC filings, press releases, public conference calls and webcasts. We use these channels, as well as social media and blogs, to communicate with our investors and the public about our company and our products. It is possible that the information we post on our websites, social media and blogs could be deemed to be material information. Therefore, we encourage investors, the media and others interested in our company to review the information we post on the websites, social media channels and blogs, including the following (which list we will update from time to time on our investor relations website):

WebsitesSocial Media
motorsportgames.comTwitter: @msportgames & @traxiongg
traxion.ggInstagram: msportgames & traxiongg
motorsport.comFacebook: Motorsport Games & traxiongg
 LinkedIn: Motorsport Games
 Twitch: traxiongg
 Reddit: traxiongg

The contents of these websites and social media channels are not part of, nor will they be incorporated by reference into, this press release.

Press:
ASTRSK PR
motorsportgames@astrskpr.com

Release – Cocrystal Pharma to Present at the Dawson James Securities 2022 Small Cap Growth Conference

Posted on by aweinsoff@channelchek.com

Research, News, Market Data on COCP

OCTOBER 05, 2022

BOTHELL, Wash., Oct. 05, 2022 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that James Martin, CFO and interim co-CEO, will present a company overview at the Dawson James Securities 2022 Small Cap Growth Conference on Wednesday, October 12, 2022 at 1:00 p.m. Eastern time (10:00 a.m. Pacific time). The conference is being held at the Wyndham Grand Hotel in Jupiter, Fla.

Mr. Martin is available throughout the conference for one-on-one meetings. The Cocrystal presentation will be posted to the IR Calendar of the Company’s website beginning October 12.

About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.

Investor Contact:
LHA Investor Relations
Jody Cain
310-691-7100
jcain@lhai.com

Media Contact:
JQA Partners
Jules Abraham
917-885-7378
Jabraham@jqapartners.com

Schwazze (SHWZ) – Adding Two More Locations

Posted on by cpatches


Wednesday, October 05, 2022

Schwazze (OTCQX:SHWZ, NEO:SHWZ) is building a premier vertically integrated regional cannabis company with assets in Colorado and New Mexico and will continue to take its operating system to other states where it can develop a differentiated regional leadership position. Schwazze is the parent company of a portfolio of leading cannabis businesses and brands spanning seed to sale. The Company is committed to unlocking the full potential of the cannabis plant to improve the human condition. Schwazze is anchored by a high-performance culture that combines customer-centric thinking and data science to test, measure, and drive decisions and outcomes. The Company’s leadership team has deep expertise in retailing, wholesaling, and building consumer brands at Fortune 500 companies as well as in the cannabis sector. Schwazze is passionate about making a difference in our communities, promoting diversity and inclusion, and doing our part to incorporate climate-conscious best practices.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

More New Mexico Coverage. Management for Schwazze announced the opening of two stores on Sept. 28 and Oct. 4 of 2022 in New Mexico, specifically in Ruidoso and Clovis respectively. The openings are part of management’s goal of expansion in the New Mexico state.

Ruidoso Dispensary. The Ruidoso store is located on 360 Sudderth Drive and officially opened its doors on September 24th. The overall population for Ruidoso is at 7,879 according to a 2020 census, and has a median household income of $43,847, according to Data USA. The town is home to a nearby ski resort called Ski Apache and has an annual number of tourists of 1.9 million, according to the town’s website. We expect the dispensary to tap into the tourist revenue stream Ruidoso currently receives.


Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Comtech Telecommunications (CMTL) – A New Chapter

Posted on by cpatches


Wednesday, October 05, 2022

Comtech Telecommunications Corp. engages in the design, development, production, and marketing of products, systems, and services for advanced communications solutions in the United States and internationally. It operates in three segments: Telecommunications Transmission, Mobile Data Communications, and RF Microwave Amplifiers. The Telecommunications Transmission segment provides satellite earth station equipment and systems, over-the-horizon microwave systems, and forward error correction technology, which are used in various commercial and government applications, including backhaul of wireless and cellular traffic, broadcasting (including HDTV), IP-based communications traffic, long distance telephony, and secure defense applications. The Mobile Data Communications segment provides mobile satellite transceivers, and computers and satellite earth station network gateways and associated installation, training, and maintenance services; supplies and operates satellite packet data networks, including arranging and providing satellite capacity; and offers microsatellites and related components. The RF Microwave Amplifiers segment designs, develops, manufactures, and markets satellite earth station traveling wave tube amplifiers (TWTA) and broadband amplifiers. Its amplifiers are used in broadcast and broadband satellite communication; defense applications, such as telecommunications systems and electronic warfare systems; and commercial applications comprising oncology treatment systems, as well as to amplify signals carrying voice, video, or data for air-to-satellite-to-ground communications. The company serves satellite systems integrators, wireless and other communication service providers, broadcasters, defense contractors, military, governments, and oil companies. Comtech markets its products through independent representatives and value-added resellers. The company was founded in 1967 and is headquartered in Melville, New York.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Turn the Page. With the appointment of Ken Peterman as CEO and President, Comtech is entering a new chapter, in our view. With a track record of building and creating sustainable, profitable growth, we believe Mr. Peterman will be able to capitalize on the high-growth opportunity set in front of Comtech.

Convergence. A key theme from Mr. Peterman is the belief of a coming “convergence” between the satellite and space communications and terrestrial and wireless communications, or Comtech’s two core markets. With an unsurpassed skill set across both of these areas, we believe Comtech is uniquely positioned to capitalize on this coming convergence.


Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

ChitogenX Inc. (CHNXF) – Expanding Opportunities, FQ2 2023 Reported.

Posted on by cpatches


Tuesday, October 04, 2022

Gregory Aurand, Senior Research Analyst, Healthcare Services & Medical Devices, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

FQ2 2023 reported for period ending July 31, 2022.  As a clinical stage company, ChitogenX reported no revenues in the quarter. Expenses, both G&A and R&D, were lower than our quarter expectations, offset by higher share-based compensation expense. R&D expenses were reduced by a $500,000 (all figures in C$) grant received in May 2022 to advance the meniscus repair indication.  The result was a net loss of $1.363 million vs. expected $1.59 million.  Loss per share was $0.03 vs. expected loss of $0.03.

ChitogenX is pushing well beyond orthopedics.  The rebranding recently instituted was more than a simple name change.  The Company is leveraging its chitosan biopolymer technology expertise to attack a much larger global regenerative medicine market, including areas like oncology, neurology, and cardiology. Regenerative medicines have an inherent inability to stick to repair sites and ChitogenX seeks to resolve the problem with their ChitogenX Biopolymer. We expect the Company to establish partnerships, license the technology, or seek grants in these additional markets.


Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

The Case for Hydrogen Fuel Cell Vehicles

Posted on by phoffman@channelchek.com
Image Credit: TruckPR (Flickr)

Is Hydrogen, Not Lithium-ion, the Automotive World’s Real Future?

Lithium-ion (Li-ion) batteries provide incredibly functional and versatile storage of electric power for cell phones, laptops, leaf blowers, Bluetooth speakers, and a myriad of other portable electric tools and appliances. But is it the best way to store power to drive the big motors found in a car or tractor-trailer? Hydrogen could provide a lighter, more potent, less environmentally harmful way to store power. And with greater range. Are car companies being steered down an inferior or potentially impossible path?

China plans to have a million hydrogen-powered vehicles on roads by 2035, and Japan, which has a much smaller population, is shooting for 800,000 units by 2030. Perhaps the world’s most abundant element is worth a deeper look before billions are spent on infrastructure to support the Li-ion model.

What’s a Fuel Cell

According to ThoughtCo.com, the most abundant element in the universe is hydrogen, making up about three-quarters of all things. Helium, then oxygen, makes up most of the rest of all matter. By comparison, all of the other elements are rare.

There are combustion engines that run on hydrogen, but it’s fuel cell electric vehicles (FCEVs) that are driven by motors, similar to those now going into Fords, Teslas and Volvos. The FCEV uses a hydrogen fuel cell.

These electric power storing fuel cells consist of a positive (cathode) and a negative electrode (anode), separated by an electrolyte membrane to chemically release electricity. This happens when oxygen from the surrounding air is exposed to the cathode. As liquid hydrogen, which fills the fuel cell in similar quantities that may be required of gas or diesel in a fossil fuel-powered vehicle, accumulates on the anode, they break apart into protons and electrons from the reaction with the electrolyte.

As protons travel through the membrane to the cathode, electrons are forced through a circuit. The circuit includes the electric motor, which releases the power to drive the vehicle down the road,  powering an electric motor in the process. The electrons complete the path and reach the protons on the cathode; here, they react with oxygen to create H20 vapor.

Benefits to Cars and Trucks

The emissions of an FCEV, if you can call it that, is pure water. This is the very definition of clean and sustainable for the planet. In fact, the water vapor released is completely recyclable. But with it being composed of two of the most abundant elements, the need to recycle it as a way to store energy doesn’t exist.

Cars and large trucks have a far longer range than battery electric vehicles (BEVs). The fuel cells can convert far more stored hydrogen into electricity than current EV batteries, making their range more in line with what drivers of cars and trucks expect from their vehicles.

The speed of powering up the fuel cell is also similar to refueling a vehicle with petrol. Refilling the fuel cell takes minutes. The combination of longer range and speed to get back on the road makes it a functionally attractive option for drivers.

Downside

Similar to recharging a lithium-ion battery, a power source is needed. Currently, this power source isn’t often wind, solar, or tidal, it’s fossil fuels. Hydrogen produced by coal or oil is seen as having dirty electrons; hydrogen produced by natural gas is called blue hydrogen. Using wind or sun to turn water into its atomic components is possible and does not need to be done in a large refinery in some remote place, but the outlets for this still need to be built.

The main reason is the lack of infrastructure. In order for hydrogen cars to become a viable option, there needs to be a network of refueling stations in place. This is a chicken-and-egg situation as car manufacturers are reluctant to mass-produce FCEVs without the existing infrastructure, and investors are unwilling to build hydrogen refueling stations without strong demand for them. Sales of fuel cell-powered vehicles in the U.S. in 2021 totaled 3,341. There aren’t entrepreneurs or even energy companies racing out to build a hydrogen refilling station when they’re not likely to experience any business.

Take Away

Although hydrogen still isn’t becoming a mainstream option, it is an alternative fuel source that is certainly worth keeping an eye on. With the right infrastructure in place, hydrogen cars could become a viable option for those looking for a clean and sustainable way to power their vehicles — if not now, definitely in the future.

Paul Hoffman

Managing Editor, Channelchek

Sources

https://insideevs.com/news/565185/us-hydrogen-car-sales-2021/

https://www.thoughtco.com/most-abundant-element-in-the-universe-602186

https://www.marketwatch.com/story/battery-electric-cars-are-the-future-not-so-fast-hydrogen-powered-cars

Oil Prices, Politics, and Dollar Strength

Posted on by phoffman@channelchek.com
Image Credit: SETShots (Flickr)

Did OPEC+ Undermine US Strategic Reserve Efforts?

The Organization of Petroleum Exporting Countries (OPEC) and the extended Russia-led allies )making it OPEC+) just agreed to slash two million barrels a day from the global petroleum markets. This is likely to nudge the cost of energy up around the globe. Oil and gas had been trending down in the U.S. in part the result of President Biden’s authorized release of one million barrels a day into the market from the U.S. Strategic Petroleum Reserve back in March.

The move by OPEC+, which counteracts efforts in the U.S. to bring prices down, should have the effect of pushing up global energy prices and benefiting oil-exporting countries such as Russia increase revenue per barrel.  

The Russian-Ukraine war has had an impact on crude prices since Russia is a major exporter of the commodity.  Prices in the futures market have been falling since June, and are currently near their pre-war levels. The softening in the market price may not be a function of supply, writes Michael Heim, CFA, Senior Research Analyst, at Noble Capital Markets, in his quarterly Energy Industry Report. Heim says they believe, “…recent weakness largely reflects demand concerns and foreign currency changes but is not a condition of oversupply.” Explaining the connection between dollar strength and oil, Heim added, “Historically, oil prices are lower when the dollar is stronger. This is because most oil suppliers, including international suppliers, demand payments in dollars.”

WTI prices peaked at $120 per barrel in the first week of June. According to Heim, since the peak, they have come down as a “response to signs of a global economic slowdown as governments raise interest rates to fight inflation.” Oil on the futures market is down nearly 50% from its 2022 peak.  

Oil Prices and Politics

OPEC+ has said they are seeking to prevent price swings rather than to target a particular oil price. Benchmark Brent crude is trading at $92 per barrel after the announcement. “The decision is technical, not political,” United Arab Emirates Energy Minister Suhail al-Mazroui told reporters ahead of the meeting.

The actions announced by OPEC+ may cause the NOPEC Bill (No Oil Producing and Exporting Cartels)    that passed the Senate Judiciary Committee back in May to resurface and gain traction. The bipartisan NOPEC bill would change U.S. antitrust law to revoke the sovereign immunity that has long protected OPEC and its national oil companies from lawsuits. Under the Bill, the U.S. attorney general would have the ability to sue the oil cartel or its members, in federal court.

The West has accused Russia of weaponizing energy and orchestrating a crisis in Europe that could trigger rationing power this winter with the potential for gas shortages. This has become a hot issue with humanitarian implications that may help the West paint cartel members in a less than flattering or even adversarial light. While the West is busy accusing Russia of using energy exports in inappropriate ways, Moscow has accused the U.S. and it allies of weaponizing the dollar and financial systems such as SWIFT in retaliation for Russia sending troops into Ukraine in February. SWIFT is a method the U.S. Treasury uses to sanction international suppliers of Russian companies.

While Saudi Arabia has not condemned Moscow’s actions in Ukraine, U.S. officials have said part of the reason Washington wants lower oil prices is to deprive Moscow of oil revenue.

Take Away

Oil will continue to be an interesting sector. The variables impacting price, which have an impact on the broader energy sector include a slowing global economy, ability, and willingness for countries such as the U.S. to tap oil reserves, length of time the Russia and Ukraine war is prolonged, rigs put online, OPEC’s ability to produce at levels targeted, and dollar strength which increases energy costs for those whose native currency is weaker than U.S. petrodollars.

Subscribe to Channelchek and receive emails each day on many industries, including oil and natural gas, as well as in-depth analysis of small-cap energy opportunities.

Paul Hoffman

Managing Editor, Channelchek

Sources

https://www.grassley.senate.gov/news/news-releases/judiciary-committee-advances-grassleys-bipartisan-nopec-act

https://www.channelchek.com/news-channel/energy-industry-report-oil-prices-have-fallen-but-its-not-because-of-supply

https://www.wsj.com/articles/opec-agrees-to-biggest-oil-production-cut-since-start-of-pandemic-11664978144?mod=djem_EnergyJournal

https://www.reuters.com/business/energy/opec-heads-deep-supply-cuts-clash-with-us-2022-10-04/

https://home.treasury.gov/news/press-releases/jy0981

Release – Schwazze Opens Another New Mexico Cannabis Dispensary Located In Clovis; Brings Total R.Greenleaf Count to 12 Stores

Posted on by aweinsoff@channelchek.com

Research, News, and Market Data on SHWZ

Grand Opening Event Scheduled for Saturday, October 15th

DENVER, Oct. 4, 2022 /PRNewswire/ – Schwazze, (OTCQX: SHWZ) (NEO: SHWZ) (“Schwazze” or the “Company”), a premier vertically integrated, multi-state operating cannabis company with assets in Colorado and New Mexico, announces the grand opening of its adult-use dispensary, R.Greenleaf, located in Clovis, New Mexico. The new store, located at 2009 Ross Street in Clovis, officially opened its doors for business on Saturday, October 1st. Regular store operating hours are 9a to 8p Sunday through Saturday.

This store opening continues the deliberate expansion throughout the state of New Mexico and comes on the heels of the September 24th store opening in Ruidoso. This brings R.Greenleaf’s number of New Mexico retail dispensaries to 12. All locations serve the needs of medical patients as well as recreational adult-use consumers.

“Schwazze is excited to add our second new retail dispensary in New Mexico within the last week and since adult recreational cannabis was legalized in New Mexico on April 1st,” said Steve Pear, New Mexico Division President for Schwazze. “We are honored to bring our support to the Clovis community. R.Greenleaf offers a wide variety of quality products and is serviced by top-notch, knowledgeable staff.”

Grand opening product specials and promotions are already in full swing with multiple flower pack offers, pre-rolls, gummies, chocolates and distillate vaporizer cartridges. Bundled kits, deals and cannabis product starter packs will be offered to provide patients and recreational customers a variety of product forms and consumption methods based on individual needs and preferences.

A grand opening celebration will be held on Saturday, October 15th beginning at 9a and running until 2p. Swag bags will be available to the first 75 shoppers with one lucky customer receiving a 50% discount coupon. Music will accompany a food truck offering free burritos and tacos to the first 75 customers making a purchase.

Clovis Store Location
R.Greenleaf
2009 Ross Street
Clovis, New Mexico 88101

Grand Opening Celebration
Saturday, October 15th
9a to 2p

Since April 2020, Schwazze has acquired, opened or announced the planned acquisition of 37 cannabis retail dispensaries as well as seven cultivation facilities and two manufacturing plants in Colorado and New Mexico. In May 2021, Schwazze announced its Biosciences division and in August 2021 it commenced home delivery services in Colorado.

About Schwazze

Schwazze (OTCQX: SHWZ) (NEO: SHWZ) is building a premier vertically integrated regional cannabis company with assets in Colorado and New Mexico and will continue to take its operating system to other states where it can develop a differentiated regional leadership position. Schwazze is the parent company of a portfolio of leading cannabis businesses and brands spanning seed to sale. The Company is committed to unlocking the full potential of the cannabis plant to improve the human condition. Schwazze is anchored by a high-performance culture that combines customer-centric thinking and data science to test, measure, and drive decisions and outcomes. The Company’s leadership team has deep expertise in retailing, wholesaling, and building consumer brands at Fortune 500 companies as well as in the cannabis sector. Schwazze is passionate about making a difference in our communities, promoting diversity and inclusion, and doing our part to incorporate climate-conscious best practices.

Medicine Man Technologies, Inc. was Schwazze’s former operating trade name. The corporate entity continues to be named Medicine Man Technologies, Inc. Schwazze derives its name from the pruning technique of a cannabis plant to enhance plant structure and promote healthy growth.

Forward-Looking Statements

This press release contains “forward-looking statements.” Such statements may be preceded by the words “plan,” “will,” “may,” “continue,” “predicts,” or similar words. Forward-looking statements are not guarantees of future events or performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified. Consequently, actual events and results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our products and product candidates on a commercial scale on our own or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; (v) difficulties in securing regulatory approval to market our products and product candidates; (vi) our ability to successfully execute our growth strategy in Colorado and outside the state, (vii) our ability to consummate the acquisition described in this press release or to identify and consummate future acquisitions that meet our criteria, (viii) our ability to successfully integrate acquired businesses, including the acquisition described in this press release, and realize synergies therefrom, (ix) the ongoing COVID-19 pandemic, * the timing and extent of governmental stimulus programs, and (xi) the uncertainty in the application of federal, state and local laws to our business, and any changes in such laws. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise except as required by law.

SOURCE Schwazze

Release – Alvopetro Announces Drilling Results from the 182-C2 Well and September 2022 Sales Volumes

Posted on by aweinsoff@channelchek.com

Research, News, and Market Data on ALVOF

Oct 04, 2022

CALGARY, AB, Oct. 4, 2022 /CNW/ – Alvopetro Energy Ltd. (TSXV: ALV) (OTCQX: ALVOF). We are pleased to announce drilling results from our 182-C2 well.  We completed drilling the 182-C2 well to a total measured depth (“MD”) of 3,185 metres on our 100% owned and operated Block 182 in the Recôncavo basin.

Based on open-hole wireline logs, at 2,607 metres total vertical depth (“TVD”), the well encountered 10.9 metres of potential net hydrocarbon pay in the Agua Grande Formation, with an average porosity of 8.9% and average water saturation of 25.1%, using a 6% porosity cut-off, 50% Vshale cut-off and 50% water saturation cut-off.

The 182-C2 well also encountered a 223.7-metre-thick section in the Sergi Formation with 121.3 metres of sand estimated above 6% porosity in the sand-dominated interval between 2,704.1 and 2,927.8 metres TVD. Caliper logs indicate that a significant amount of the wellbore in the Sergi interval contains washouts from drilling and is out of gauge, making open-hole log analysis challenging. As such, hydrocarbon potential in the Sergi will be validated through formation testing. 

Based on these drilling results, we plan to case the well and undertake a multi-zone testing program of the 182-C2 well. This testing will assess the extent, if any, of commercial hydrocarbons associated with the well, the productive capability of the well and will help define the field development plan. 

Operational Update

On our Murucututu project, we are completing the commissioning of our 183-1 field production facility and expect to have commercial natural gas and condensate sales from the 183-1 well this month.

We are completing service rig inspection and acceptance testing and expect to commence a multizone production test of our 183-B1 well later this week. 

September Sales Volumes

September sales volumes averaged 2,686 boepd, including natural gas sales of 15.4 MMcfpd and associated natural gas liquids sales from condensate of 124 bopd, based on field estimates.  Our sales volumes averaged 2,642 boepd in the third quarter of 2022, an increase of 12% from the second quarter of 2022. 

Corporate Presentation

Alvopetro’s updated corporate presentation is available on our website at:

http://www.alvopetro.com/corporate-presentation. 

Social Media

Follow Alvopetro on our social media channels at the following links:Twitter – https://twitter.com/AlvopetroEnergyInstagram – https://www.instagram.com/alvopetro/LinkedIn – https://www.linkedin.com/company/alvopetro-energy-ltdYouTube – https://www.youtube.com/channel/UCgDn_igrQgdlj-maR6fWB0w

Alvopetro Energy Ltd.’s vision is to become a leading independent upstream and midstream operator in Brazil. Our strategy is to unlock the on-shore natural gas potential in the state of Bahia in Brazil, building off the development of our Caburé natural gas field and our strategic midstream infrastructure.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

All amounts contained in this new release are in United States dollars, unless otherwise stated and all tabular amounts are in thousands of United States dollars, except as otherwise noted.

Abbreviations:boepd                    =              barrels of oil equivalent (“boe”) per daybopd                      =              barrels of oil and/or natural gas liquids (condensate) per dayMBOE                   =              thousands of barrels of oil equivalentMMcf                     =              million cubic feetMMcfpd                 =              million cubic feet per day

BOE Disclosure. The term barrels of oil equivalent (“boe”) may be misleading, particularly if used in isolation. A boe conversion ratio of six thousand cubic feet per barrel (6Mcf/bbl) of natural gas to barrels of oil equivalence is based on an energy equivalency conversion method primarily applicable at the burner tip and does not represent a value equivalency at the wellhead. All boe conversions in this news release are derived from converting gas to oil in the ratio mix of six thousand cubic feet of gas to one barrel of oil.

Testing and Well Results.  Data obtained from the 182-C2 well identified in this press release, including hydrocarbon shows, open-hole logging, net pay and porosities, should be considered to be preliminary until testing, detailed analysis and interpretation has been completed. Hydrocarbon shows can be seen during the drilling of a well in numerous circumstances and do not necessarily indicate a commercial discovery or the presence of commercial hydrocarbons in a well. There is no representation by Alvopetro that the data relating to the 182-C2 well contained in this press release is necessarily indicative of long-term performance or ultimate recovery. The reader is cautioned not to unduly rely on such data as such data may not be indicative of future performance of the well or of expected production or operational results for Alvopetro in the future.

Cautionary statements regarding the filing of a Notice of Discovery. We have submitted a Notice of Discovery of Hydrocarbons to the Agência Nacional do Petróleo, Gás Natural e Biocombustíveis (the “ANP”) with respect to the 182-C2 well. All operators in Brazil are required to inform the ANP, through the filing of a Notice of Discovery, of potential hydrocarbon discoveries. A Notice of Discovery is required to be filed with the ANP based on hydrocarbon indications in cuttings, mud logging or by gas detector, in combination with wire-line logging. Based on the results of open-hole logs, we have filed a Notice of Discovery relating to our 182-C2 well. These routine notifications to the ANP are not necessarily indicative of commercial hydrocarbons, potential production, recovery or reserves.

Forward-Looking Statements and Cautionary Language. This news release contains “forward-looking information” within the meaning of applicable securities laws. The use of any of the words “will”, “expect”, “intend” and other similar words or expressions are intended to identify forward-looking information. Forward‐looking statements involve significant risks and uncertainties, should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether or not such results will be achieved. A number of factors could cause actual results to vary significantly from the expectations discussed in the forward-looking statements. These forward-looking statements reflect current assumptions and expectations regarding future events. Accordingly, when relying on forward-looking statements to make decisions, Alvopetro cautions readers not to place undue reliance on these statements, as forward-looking statements involve significant risks and uncertainties. More particularly and without limitation, this news release contains forward-looking information concerning potential hydrocarbon pay in the 183-C2 well, anticipated production commencement on our Murucututu project, exploration and development prospects of Alvopetro and the expected timing of certain of Alvopetro’s testing and operational activities. The forward‐looking statements are based on certain key expectations and assumptions made by Alvopetro, including but not limited to expectations and assumptions concerning testing results of the 183-B1 well and the 182-C2 well, equipment availability, the timing of regulatory licenses and approvals, the success of future drilling, completion, testing, recompletion and development activities, the outlook for commodity markets and ability to access capital markets, the impact of the COVID-19 pandemic, the performance of producing wells and reservoirs, well development and operating performance, foreign exchange rates, general economic and business conditions, weather and access to drilling locations, the availability and cost of labour and services, environmental regulation, including regulation relating to hydraulic fracturing and stimulation, the ability to monetize hydrocarbons discovered, expectations regarding Alvopetro’s working interest and the outcome of any redeterminations, the regulatory and legal environment and other risks associated with oil and gas operations. The reader is cautioned that assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be incorrect. Actual results achieved during the forecast period will vary from the information provided herein as a result of numerous known and unknown risks and uncertainties and other factors.  Although Alvopetro believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because Alvopetro can give no assurance that it will prove to be correct. Readers are cautioned that the foregoing list of factors is not exhaustive. Additional information on factors that could affect the operations or financial results of Alvopetro are included in our annual information form which may be accessed on Alvopetro’s SEDAR profile at www.sedar.com. The forward-looking information contained in this news release is made as of the date hereof and Alvopetro undertakes no obligation to update publicly or revise any forward-looking information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.

SOURCE Alvopetro Energy Ltd.

Release – Lineage to Present at Alliance for Regenerative Medicine 2022 Cell and Gene Meeting on the Mesa

Posted on by aweinsoff@channelchek.com

Research, News, and Market Data on LCTX

October 4, 2022 at 8:00 AM EDT

CARLSBAD, Calif.–(BUSINESS WIRE)–Oct. 4, 2022– Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that Brian M. Culley, Lineage’s Chief Executive Officer, will present at the Alliance for Regenerative Medicine 2022 Cell & Gene Meeting on the Mesa, on October 12th, 2022 at 2:15pm PT / 5:15pm ET at the Park Hyatt Aviara, Carlsbad, CA. Virtual meeting attendance is available and includes a livestream of Lineage’s presentation and the ability to view all conference sessions on-demand. Interested parties can visit the 2022 Cell & Gene Meeting on the Mesa website for full information on the conference, including registration.

The Cell & Gene Meeting on the Mesa is the sector’s foremost annual conference bringing together senior executives and top decision-makers in the industry to advance cutting-edge research into cures. Tackling the commercialization hurdles facing the cell and gene therapy sector today, this meeting covers a wide range of topics from clinical trial design to alternative payment models to scale-up and supply chain platforms for advanced therapies. The program features expert-led panels, extensive partnering capabilities, exclusive networking opportunities, and dedicated presentations by the leading publicly traded and privately held companies in the space. This conference enables key partnerships through more than 3,000 one-on-one meetings while highlighting the significant clinical and commercial progress in the field.

About the Alliance for Regenerative Medicine

The Alliance for Regenerative Medicine (ARM) is the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies. ARM promotes legislative, regulatory, reimbursement and manufacturing initiatives to advance this innovative and transformative sector, which includes cell therapies, gene therapies and tissue-engineered therapies. In its 13-year history, ARM has become the global voice of the sector, representing the interests of 450+ members worldwide, including small and large companies, academic research institutions, major medical centers and patient groups.

About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include five allogeneic (“off-the-shelf”) product candidates: (i) OpRegen, a retinal pigment epithelial cell therapy in development for the treatment of geographic atrophy secondary to age-related macular degeneration, is being developed under a worldwide collaboration with Roche and Genentech, a member of the Roche Group; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; (iii) VAC2, a dendritic cell therapy produced from Lineage’s VAC technology platform for immuno-oncology and infectious disease, currently in Phase 1 clinical development for the treatment of non-small cell lung cancer; (iv) ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; and (v) PNC1, a photoreceptor neural cell therapy for the treatment of vision loss due to photoreceptor dysfunction or damage. For more information, please visit www.lineagecell.com or follow the company on Twitter @LineageCell.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221004005157/en/

Lineage Cell Therapeutics, Inc. IR
Ioana C. Hone
(ir@lineagecell.com)
(442) 287-8963

LifeSci Advisors
Daniel Ferry
(daniel@lifesciadvisors.com)
(617) 430-7576

Russo Partners – Media Relations
Nic Johnson or David Schull
(Nic.johnson@russopartnersllc.com)
(David.schull@russopartnersllc.com)
(212) 845-4242

Source: Lineage Cell Therapeutics, Inc.